Roobol MJ - Search Results

1

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG. Drost FH, et al. Among authors: roobol mj. Cochrane Database Syst Rev. 2019 Apr 25;4(4):CD012663. doi: 10.1002/14651858.CD012663.pub2. Cochrane Database Syst Rev. 2019. PMID: 31022301 Free PMC article.

2

Pathologic features of prostate cancer found at population-based screening with a four-year interval.

Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schröder FH. Hoedemaeker RF, et al. J Natl Cancer Inst. 2001 Aug 1;93(15):1153-8. doi: 10.1093/jnci/93.15.1153. J Natl Cancer Inst. 2001. PMID: 11481387 Free article. Clinical Trial.

3

Serendipity in detecting disease in low prostate-specific antigen ranges.

Vis AN, Kranse R, Roobol M, van der Kwast TH, Schröder FH. Vis AN, et al. BJU Int. 2002 Mar;89(4):384-9. doi: 10.1046/j.1464-4096.2001.01868.x. BJU Int. 2002. PMID: 11872029 Clinical Trial.

4

Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).

Roobol MJ, Kranse R, de Koning HJ, Schröder FH. Roobol MJ, et al. Urology. 2004 Feb;63(2):309-13; discussion 313-5. doi: 10.1016/j.urology.2003.09.083. Urology. 2004. PMID: 14972478

5

Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.

Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH. Raaijmakers R, et al. Among authors: roobol mj. Urology. 2004 Feb;63(2):316-20. doi: 10.1016/j.urology.2003.09.028. Urology. 2004. PMID: 14972481

6

Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.

Postma R, Roobol M, Schröder FH, van der Kwast TH. Postma R, et al. Cancer. 2004 Mar 1;100(5):968-75. doi: 10.1002/cncr.20048. Cancer. 2004. PMID: 14983492 Free article. Clinical Trial.

7

No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).

Roobol MJ, van der Cruijsen IW, Schröder FH. Roobol MJ, et al. Urology. 2004 May;63(5):892-7; discussion 897-9. doi: 10.1016/j.urology.2003.12.042. Urology. 2004. PMID: 15134973 Clinical Trial.

8

Lesions predictive for prostate cancer in a screened population: first and second screening round findings.

Postma R, Roobol M, Schröder FH, van der Kwast TH. Postma R, et al. Prostate. 2004 Nov 1;61(3):260-6. doi: 10.1002/pros.20105. Prostate. 2004. PMID: 15368469

9

Rotterdam randomized pilot studies of screening for prostate cancer--an overview after 10 years.

Schröder FH, Roobol MJ, Damhuis RA, de Koning HJ, Blijenberg BG, Van der Kwast TH, Kirkels WJ, Bangma CH. Schröder FH, et al. Among authors: roobol mj. J Natl Cancer Inst. 2005 May 4;97(9):696. doi: 10.1093/jnci/dji121. J Natl Cancer Inst. 2005. PMID: 15870441 No abstract available.

10

4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.

Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ. Schröder FH, et al. Among authors: roobol mj. J Urol. 2005 Aug;174(2):489-94; discussion 493-4. doi: 10.1097/01.ju.0000165568.76908.5c. J Urol. 2005. PMID: 16006878

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

507 results

Search Page

Filters